Frequently Asked Questions
Can't find what you're looking for? Email us, we respond to every message.
Research Peptides, Retatrutide & GLP-1
What is Retatrutide?
Retatrutide (research code LY3437943) is a synthetic peptide and a triple receptor agonist, it simultaneously activates the GLP-1, GIP, and Glucagon receptors. It is the most advanced multi-receptor compound currently in clinical development in the GLP-1 class. As of 2026 it is in Phase 3 trials (the TRIUMPH programme). See the Retatrutide Research Guide for full mechanism, trial data, and reconstitution detail.
How is Retatrutide different from Tirzepatide?
Both are synthetic peptides developed by Eli Lilly. Tirzepatide is a dual agonist (GLP-1 + GIP receptors). Retatrutide adds a third target, the Glucagon receptor, which engages hepatic thermogenesis and fat oxidation pathways that dual agonists do not. Phase 2 Retatrutide data (NEJM 2023) reported up to 24.2% mean body weight reduction at 48 weeks; SURMOUNT-1 Tirzepatide data reported 20.9% at 72 weeks. These are cross-trial comparisons, not a head-to-head study. See Retatrutide vs Tirzepatide.
What does GLP-1 stand for?
GLP-1 is short for Glucagon-Like Peptide-1, an incretin hormone produced in the gut that stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. GLP-1 receptor agonists are synthetic peptides that bind the same receptor as the natural hormone. Semaglutide is a single-receptor GLP-1 agonist; Tirzepatide adds GIP receptor agonism; Retatrutide adds both GIP and Glucagon receptor agonism.
What is the current developmental status of Retatrutide?
Retatrutide is in Phase 3 clinical trials (the TRIUMPH programme) as of 2026. The programme includes trials in obesity (TRIUMPH-1), type 2 diabetes, and cardiovascular outcomes. Headline Phase 3 results are anticipated in 2026–2027. It is not approved as a therapeutic in Australia or any other jurisdiction at the time of writing. See the Retatrutide Phase 3 update.
What receptors does Retatrutide target?
Three receptors simultaneously: GLP-1R (Glucagon-Like Peptide-1 Receptor), GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor), and GcgR (Glucagon Receptor). The triple-agonism is the mechanistic basis for its observed effects on appetite suppression, insulin sensitisation, and thermogenesis.
What body weight reduction has been reported in Retatrutide trials?
Phase 2 trial data published in the New England Journal of Medicine (2023) reported mean body weight reductions of up to 24.2% at the 12mg dose cohort over 48 weeks. Lower-dose cohorts (4mg, 8mg) showed dose-dependent responses of approximately 8.7% and 17.3% respectively. Phase 3 (TRIUMPH) results are anticipated in 2026–2027.
How is Retatrutide reconstituted?
Lyophilised Retatrutide is reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water). Standard research protocols use 1–3 mL of bacteriostatic water per vial depending on target concentration. Slowly inject the diluent down the side of the vial, swirl gently (do not shake), and store the reconstituted solution at 2–8°C. See the reconstitution and storage guide for full protocol and the reconstitution calculator for per-vial volumes.
Who developed Retatrutide?
Retatrutide was developed by Eli Lilly & Company under the research code LY3437943. The compound was designed by Lilly's peptide chemistry group as the first triple receptor agonist (GLP-1 + GIP + Glucagon) to advance to human trials. The Phase 2 dose-finding study was led by Ania Jastreboff and colleagues (Yale and Lilly) and published in the New England Journal of Medicine in June 2023.
What is the half-life of Retatrutide?
Approximately 6 days, derived from Phase 1 pharmacokinetic data (Coskun et al., Nature Metabolism 2022). This supports once-weekly subcutaneous dosing, the schedule used throughout Phase 2 and the Phase 3 TRIUMPH programme. Steady-state plasma concentrations are typically reached at around 4–5 weeks of consistent weekly dosing.
How is Retatrutide different from Semaglutide?
Semaglutide is a single GLP-1 receptor agonist. Retatrutide is a triple agonist that adds two more receptor targets, GIPR and the Glucagon Receptor. The mechanism translates into different Phase data: Semaglutide STEP 1 reported 14.9% mean body weight loss at 68 weeks (2.4mg/week); Retatrutide Phase 2 reported 24.2% at 48 weeks (12mg/week). Cross-trial comparison, not head-to-head. See Retatrutide vs Semaglutide.
What does "triple agonist" mean?
A triple agonist is a single peptide that simultaneously activates three different receptors. Retatrutide is the first triple agonist in clinical development that targets the three primary metabolic receptors of interest: GLP-1R (appetite suppression + insulin secretion), GIPR (insulin amplification + adipose effects), and GcgR (hepatic energy expenditure + thermogenesis). Engineering a single molecule that engages all three is what distinguishes Retatrutide from earlier single-receptor or dual-receptor compounds.
Why does Retatrutide add the Glucagon Receptor when glucagon raises blood sugar?
In isolation, glucagon receptor agonism would raise blood glucose, that is glucagon's classical role. Retatrutide design balances this by co-activating GLP-1R, which drives glucose-dependent insulin secretion that offsets the glucagon effect. The benefit retained from glucagon receptor agonism is the thermogenic / fat-oxidation pathway in liver and adipose tissue, which adds an energy-expenditure mechanism that pure GLP-1 or dual GLP-1/GIP agonists do not engage. See Glucagon Receptor Explained.
What is the TRIUMPH programme?
TRIUMPH is Eli Lilly's Phase 3 development plan for Retatrutide. As of 2026 it spans ten registered trials (TRIUMPH-1 through TRIUMPH-9 plus TRIUMPH-Outcomes); the core registrational studies are TRIUMPH-1 (obesity, ~2,335 enrolled), TRIUMPH-2 (type 2 diabetes, ~1,000), TRIUMPH-3 (obesity + cardiovascular disease, ~1,946), TRIUMPH-4 (obesity + knee osteoarthritis, ~445), and TRIUMPH-Outcomes (cardiovascular and kidney outcomes MACE, ~10,000). TRIUMPH-1 reported topline results in May 2026 (28.3% mean weight loss at 12mg over 80 weeks); primary endpoint data from TRIUMPH-3 is anticipated in late 2026 to mid-2027. See the Phase 3 TRIUMPH update.
Are Australian research sites involved in Retatrutide Phase 3?
Yes. TRIUMPH-3 (obesity + cardiovascular disease) lists the University of Sydney Boden Initiative as an active enrolment site. TRIUMPH-Outcomes (cardiovascular and kidney outcomes MACE) has multiple Australian cardiology centres participating. Other TRIUMPH studies have selected Australian sites. Active site lists can be verified at clinicaltrials.gov against each NCT identifier.
What is the NCT identifier for the Retatrutide Phase 2 trial?
NCT04881760. The trial was registered on ClinicalTrials.gov as a Phase 2 randomised, double-blind, placebo-controlled study of LY3437943 in adults with obesity, enrolling 338 participants across six cohorts (placebo, 1mg, 4mg slow titration, 4mg fast titration, 8mg, 12mg weekly). Primary endpoint was percentage change in body weight at 48 weeks. Results published in NEJM 28 June 2023.
What endpoints did the Retatrutide Phase 2 trial measure besides weight?
Secondary endpoints at the 12mg cohort included approximately 41% mean reduction in fasting insulin, 43% mean reduction in triglycerides, 18.5cm mean reduction in waist circumference, and a meaningful reduction in liver fat fraction on MRI in the measured subset. Cardiometabolic biomarkers including HbA1c, LDL cholesterol, and blood pressure also improved across active-treatment cohorts.
What dose escalation schedule was used in Phase 2?
All active Phase 2 cohorts initiated at 2mg/week and stepped up at 4-week intervals. The 4mg cohort reached 4mg/week at week 5. The 8mg cohort escalated 2 → 4 → 6 → 8 mg with maintenance from week 13. The 12mg cohort escalated 2 → 4 → 8 → 10 → 12 mg with maintenance from week 17. The 1mg cohort was dosed at 1mg/week throughout with no escalation. See the dosing protocol reference.
How long is reconstituted Retatrutide stable?
Reconstituted Retatrutide in bacteriostatic water is stable for approximately 4 weeks when stored refrigerated at 2–8°C. Do not freeze the reconstituted solution, freeze-thaw cycles can cause peptide aggregation. For research protocols longer than 4 weeks, reconstitute fresh aliquots from the frozen lyophilised stock. Label reconstituted vials with the date and concentration. See the reconstitution and storage guide.
What concentration is standard for Retatrutide reconstitution?
Most research protocols target 10mg/mL by adding 1.0mL bacteriostatic water to a 10mg vial, 2.0mL to a 20mg vial, or 3.0mL to a 30mg vial. The 10mg/mL standard simplifies dose volume calculations, 1mg = 0.1mL = 10 units on a U100 insulin syringe. The reconstitution calculator outputs per-dose volumes for any vial size and target concentration.
Can a Retatrutide vial be split across multiple doses?
Yes (this is the standard research protocol approach. Reconstitution produces a multi-dose vial. The bacteriostatic water diluent contains 0.9% benzyl alcohol as a preservative, which permits multiple withdrawals over the 4-week stability window. Use a fresh sterile syringe and needle for each withdrawal. A 20mg vial reconstituted to 10mg/mL provides 20mg total) sufficient for 10 doses at 2mg each, or 2.5 doses at 8mg each.
What are the most common adverse events in Retatrutide research?
Gastrointestinal events dominate the Phase 2 adverse event profile, consistent with the GLP-1 class. At the 12mg cohort: nausea ~42%, vomiting ~20%, diarrhoea ~18%, constipation ~14%, decreased appetite in the majority of subjects. Injection site reactions occurred in ~8%. Events were concentrated in the early titration weeks and were dose-dependent. See Retatrutide side effects (Phase 2 data) for full breakdown.
What was the discontinuation rate at the highest Phase 2 dose?
In the 12mg cohort: approximately 6.4% AE-driven discontinuation and approximately 22% all-cause discontinuation over 48 weeks. The 8mg cohort showed approximately 6.3% AE-driven and 21% all-cause. Lower-dose cohorts (1mg, 4mg) showed 4.5–4.7% AE-driven discontinuation. Most discontinuations occurred during the early titration window (weeks 1–12) and were attributed to GI adverse events.
Were any serious adverse events reported in Retatrutide Phase 2?
Serious adverse events (SAEs) occurred at approximately 6% in the 12mg cohort and approximately 5% in placebo, similar incidence. No cases of pancreatitis, thyroid C-cell tumours, or severe hypoglycaemia were reported across any active cohort during the 48-week trial. Long-term safety beyond 48 weeks is being characterised in the ongoing Phase 3 TRIUMPH programme.
Why is there no head-to-head trial of Retatrutide vs Tirzepatide?
No head-to-head trial has been conducted because both compounds are developed by the same company (Eli Lilly). A sponsor running a direct comparison would create commercial cannibalisation risk between their own products. All Retatrutide-vs-Tirzepatide comparisons in the research literature are cross-trial, drawn from separate studies with different populations, durations, and dose ranges. This means published comparisons support mechanistic hypotheses but cannot substitute for a controlled head-to-head study. Phase 3 TRIUMPH outcomes will clarify Retatrutide's position relative to the established Tirzepatide benchmark.
Storage & Handling
How should I store lyophilised peptides?
Store unopened lyophilised vials at −20°C, protected from light and moisture, where most peptides remain stable for 12–24 months. For active use, short-term storage at 2–8°C (refrigerator) is acceptable for up to 3 months; sequences containing Met, Cys, Trp, Asn or Gln degrade fastest. This is general guidance, always check the storage note on the specific product page. Some compounds differ: lyophilised HGH (somatropin) should be kept at 2–8°C and not frozen.
What do I use to reconstitute peptides?
Use bacteriostatic water (0.9% benzyl alcohol in sterile water). Avoid plain sterile water for multi-use vials as it lacks antimicrobial protection. See our reconstitution guide for full protocol.
How long does reconstituted peptide last?
Reconstituted peptide solution stored at 2–8°C in bacteriostatic water is stable for 4–6 weeks. Do not freeze reconstituted solution and avoid repeated freeze-thaw cycles.